                         SEQUENCE LISTING

<110>  YEDA Research and Development Co. LTD
 
<120>  GIRK AS A THERAPEUTIC TARGET OF IMMUNE DISORDERS AND A MARKER OF 
       B CELL SUBTYPES

<130>  YEDA0138 PCT

<150>  61/863447
<151>  2013-08-08

<160>  8     

<170>  PatentIn version 3.5

<210>  1
<211>  23
<212>  DNA
<213>  Artificial

<220>
<223>  Synthetic oligo

<400>  1
attttaattc actgtatctc agc                                               23


<210>  2
<211>  19
<212>  DNA
<213>  Artificial

<220>
<223>  Synthetic oligo

<400>  2
gtccttgaag aagatggtg                                                    19


<210>  3
<211>  22
<212>  DNA
<213>  Artificial

<220>
<223>  Synthetic oligo

<400>  3
gatgtctcgt gctcaactgg aa                                                22


<210>  4
<211>  20
<212>  DNA
<213>  Artificial

<220>
<223>  Synthetic oligo

<400>  4
ggcaagtcat gcctgttgct                                                   20


<210>  5
<211>  20
<212>  DNA
<213>  Artificial

<220>
<223>  Synthetic oligo

<400>  5
agcagtacag ccccaaaatg                                                   20


<210>  6
<211>  20
<212>  DNA
<213>  Artificial

<220>
<223>  Synthetic oligo

<400>  6
ggcctgtatc caacacttcg                                                   20


<210>  7
<211>  21
<212>  PRT
<213>  Artificial

<220>
<223>  Peptide

<400>  7

Ala Leu Cys Asn Cys Asn Arg Ile Ile Ile Arg His Met Cys Trp Lys 
1               5                   10                  15      


Lys Cys Gly Lys Lys 
            20      


<210>  8
<211>  37
<212>  PRT
<213>  Artificial

<220>
<223>  Peptide


<220>
<221>  misc_feature
<222>  (1)..(37)
<223>  Xaa=Pyroglutamic Acid (Glp)

<400>  8

Xaa Phe Thr Asn Val Ser Cys Thr Thr Ser Lys Glu Cys Trp Ser Val 
1               5                   10                  15      


Cys Gln Arg Leu His Asn Thr Ser Arg Gly Lys Cys Met Asn Lys Lys 
            20                  25                  30          


Cys Arg Cys Tyr Ser 
        35          


